* participants already prescribed chloroquine, hydroxychloroquine, or azithromycin * allergy to hydroxychloroquine or azithromycin * history of bone marrow transplant * known g6pd (glucose-6-phosphate dehydrogenase deficiency) deficiency * chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or glomerular filtration rate \< 20ml/min/1.73m2 * liver disease (e.g. child pugh score ≥ b or ast (aspartate transaminase)\>2 times upper limit) * psoriasis * porphyria * known cardiac conduction delay (qtc \> 500msec) or taking any prescription medications known to prolong qt interval * concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone * prisoner * weight \< 35kg * inability to follow-up - no cell phone or no address or not spanish or english speaking * receipt of any experimental treatment for sars-cov-2 (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation * no symptoms attributable to covid-19 * pregnant or nursing

* participants already prescribed chloroquine, hydroxychloroquine, or azithromycin * allergy to hydroxychloroquine or azithromycin * history of bone marrow transplant * known g6pd (glucose-6-phosphate dehydrogenase deficiency) deficiency * chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or glomerular filtration rate \< 20ml/min/1.73m2 * liver disease (e.g. child pugh score ≥ b or ast (aspartate transaminase)\>2 times upper limit) * psoriasis * porphyria * known cardiac conduction delay (qtc \> 500msec) or taking any prescription medications known to prolong qt interval * concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone * prisoner * weight \< 35kg * inability to follow-up - no cell phone or no address or not spanish or english speaking * receipt of any experimental treatment for sars-cov-2 (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation * no symptoms attributable to covid-19 * pregnant or nursing

- participants already prescribed chloroquine, hydroxychloroquine, or azithromycin - allergy to hydroxychloroquine or azithromycin - history of bone marrow transplant - known g6pd (glucose-6-phosphate dehydrogenase deficiency) deficiency - chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or glomerular filtration rate < 20ml/min/1.73m2 - liver disease (e.g. child pugh score ≥ b or ast (aspartate transaminase)>2 times upper limit) - psoriasis - porphyria - known cardiac conduction delay (qtc > 500msec) or taking any prescription medications known to prolong qt interval - concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone - prisoner - weight < 35kg - inability to follow-up - no cell phone or no address or not spanish or english speaking - receipt of any experimental treatment for sars-cov-2 (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation - no symptoms attributable to covid-19 - pregnant or nursing

- participants already prescribed chloroquine, hydroxychloroquine, or azithromycin - allergy to hydroxychloroquine or azithromycin - history of bone marrow transplant - known g6pd (glucose-6-phosphate dehydrogenase deficiency) deficiency - chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or glomerular filtration rate < 20ml/min/1.73m2 - liver disease (e.g. child pugh score ≥ b or ast (aspartate transaminase)>2 times upper limit) - psoriasis - porphyria - known cardiac conduction delay (qtc > 500msec) or taking any prescription medications known to prolong qt interval - concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone - prisoner - weight < 35kg - inability to follow-up - no cell phone or no address or not spanish or english speaking - receipt of any experimental treatment for sars-cov-2 (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation - no symptoms attributable to covid-19 - pregnant or nursing